US equities |
SPCX $168.39 ▲+5.93% NVDA $237.30 ▲+1.43% MU $1,065.63 ▼-0.86% TSLA $378.08 ▲+2.02% MSFT $525.90 ▲+1.62% INTC $116.91 ▼-2.03% SNDK $1,722.47 ▲+0.14% META $745.79 ▲+2.43%
FinancialContent

Articles published by Zymeworks Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Host First Quarter 2022 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Pricing of $100.0 Million Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Proposed Public Offering
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Reports Inducement Grant Under New York Stock Exchange Listed Company Manual Rule
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Present at 40th Annual J.P. Morgan Healthcare Conference
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Names Biotechnology Industry Leader Kenneth Galbraith as Chair and CEO to Succeed Dr. Ali Tehrani
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in Asia in Collaboration with BeiGene and Associated Milestone Payment
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Second Janssen Bispecific Antibody to Begin Clinical Development Utilizing Azymetric™ and EFECT™ Therapeutic Platforms
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Abstract for Zanidatamab in Late-Line HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium (SABCS)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Names Neil Josephson, M.D., Chief Medical Officer
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Launches Global Phase 3 Zanidatamab Trial in First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA)
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks to Present at Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Reports 2021 Third Quarter Financial Results
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks Announces Webcast to Present HERIZON-GEA-01 Pivotal Trial Design and Zanidatamab Commercial Strategy in Gastrointestinal Cancers
From Zymeworks Inc.
Via Business Wire
Tickers ZYME
News headline image
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors
From Zymeworks Inc.
Via Business Wire
Tickers ALXO ZYME
< Previous 1 2 3 4 5 6 Next >